Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Aneesha Dasgupta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7479-1149; OpenAlex author ID A5001608330; NIH RePORTER profile ID 12480809. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
2
Labs led
1
Collaborators
49
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 grant · 2026: 1 grant

Papers 16

  1. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Co-author DOI 10.1038/s41556-024-01372-4↗
  2. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 … Co-author DOI 10.1038/s41556-024-01417-8↗
  3. A TGF-β/KLF10 signaling axis regulates atrophy-associated genes to induce muscle wasting in pancreatic cancer. Co-author DOI 10.1073/pnas.2215095120↗
  4. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Co-author DOI 10.1038/s41388-021-02132-6↗
  5. Anticachectic regulator analysis reveals Perp-dependent antitumorigenic properties of 3-methyladenine in pancreatic cancer. Co-author DOI 10.1172/jci.insight.153842↗
  6. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Co-author DOI 10.1016/j.canlet.2020.04.017↗
  7. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia. First author DOI 10.1016/j.canlet.2020.07.025↗
  8. Evaluating the Metabolic Alterations in Pancreatic Cancer. Co-author DOI 10.1007/978-1-4939-8879-2_20↗
  9. Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia. First author DOI 10.1007/978-1-4939-8879-2_28↗
  10. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. Co-author DOI 10.3390/cancers11091327↗
  11. Metabolic Alterations in Pancreatic Cancer Progression. Co-author DOI 10.3390/cancers12010002↗
  12. Hypoxia-Induced Metabolomic Alterations in Pancreatic Cancer Cells. Co-author DOI 10.1007/978-1-4939-7665-2_9↗
  13. GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2017.04.029↗
  14. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  15. MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-1151↗
  16. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. First author DOI 10.18632/oncotarget.5843↗

Grants 2

  1. Targeting Perp in PDAC tumor and cancer cachexia R00CA283277↗
  2. Targeting Perp in PDAC tumor and cancer cachexia K99CA283277↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pankaj Kumar Singh · 14 shared papers, 2015–2024 · strength 1.38
  2. Surendra Kumar Shukla · 13 shared papers, 2015–2024 · strength 1.26
  3. Ryan J. King · 10 shared papers, 2015–2024 · strength 0.96
  4. Kuldeep Singh Attri · 6 shared papers, 2017–2024 · strength 0.66
  5. Venugopal Gunda · 8 shared papers, 2015–2022 · strength 0.66
  6. Scott E. Mulder · 5 shared papers, 2019–2024 · strength 0.65
  7. Divya Murthy · 6 shared papers, 2017–2024 · strength 0.63
  8. Nina V. Chaika · 7 shared papers, 2015–2024 · strength 0.63
  9. Michael Anthony Hollingsworth · 5 shared papers, 2017–2024 · strength 0.55
  10. Paul M. Grandgenett · 5 shared papers, 2017–2024 · strength 0.55
  11. Enza Vernucci · 7 shared papers, 2015–2022 · strength 0.52
  12. Jaime Abrego · 6 shared papers, 2017–2022 · strength 0.49
  13. Kamiya Mehla · 5 shared papers, 2015–2024 · strength 0.47
  14. Chunbo He · 3 shared papers, 2022–2024 · strength 0.40
  15. Ravi Kumar Thakur · 3 shared papers, 2022–2024 · strength 0.40
  16. Joshua J. Souchek · 4 shared papers, 2015–2024 · strength 0.38
  17. Vikrant Rai · 3 shared papers, 2019–2024 · strength 0.36
  18. Paige C. Arneson‐Wissink · 2 shared papers, 2022–2023 · strength 0.33
  19. Jason D. Doles · 2 shared papers, 2022–2023 · strength 0.33
  20. Robert Powers · 3 shared papers, 2017–2024 · strength 0.32
  21. Teklab Gebregiworgis · 3 shared papers, 2017–2024 · strength 0.32
  22. Rosa F. Hwang · 2 shared papers, 2024 · strength 0.28
  23. Ajay Jain · 2 shared papers, 2024 · strength 0.28
  24. Tuo Hu · 2 shared papers, 2024 · strength 0.28
  25. Sai Sundeep Kollala · 2 shared papers, 2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.